Literature DB >> 7734185

Inhibition of human immunodeficiency virus type 1 integrase by a hydrophobic cation: the phenanthroline-cuprous complex.

A Mazumder1, M Gupta, D M Perrin, D S Sigman, M Rabinovitz, Y Pommier.   

Abstract

The human immunodeficiency virus type 1 integrase (HIV-1 integrase) is required for integration of a double-stranded DNA copy of the viral RNA genome into a host chromosome and for HIV replication. We have examined the effects of 2:1 1,10-phenanthroline-cuprous complexes on purified HIV-1 integrase. Although the uncomplexed phenanthrolines are not active below 100 microM, four of the cuprous complexes (neocuproine, 4-phenyl neocuproine, 2,3,4,7,8,9-hexamethyl phenanthroline, and 2,3,4,7,8-pentamethyl phenanthroline) have a 50% inhibitory concentration (IC50) for integration ranging between 1 and 10 microM. Disintegration is also inhibited by these phenanthroline-cuprous complexes at slightly higher concentrations (between 10 and 40 microM). Dialysis experiments showed that the inhibition is reversible and kinetic analyses revealed that the mode of inhibition by these cuprous complexes appears to be noncompetitive with respect to the substrate DNA. Consistent with these findings, binding assays demonstrate that, although these complexes can inhibit binding to DNA at high concentrations, they do not inhibit binding of integrase to the DNA substrate at their IC50 values. Because these complexes do not bind to B-DNA below 50 microM, inhibition via binding to a specific region on the enzyme was examined. Using deletion mutants of integrase, it was determined that neither the amino-terminal (zinc finger) nor the carboxy-terminal (DNA-binding) integrase domain is required for inhibition by the phenanthroline-cuprous complexes. Therefore, inhibition via binding to the enzyme catalytic core or to the interface between the enzyme and a noncanonical DNA structure generated during the enzymatic reaction is the probable mechanism. These results suggest the utility of neocuproine-cuprous complexes in developing inhibitors of HIV-1 integrase as well as probes for drug-binding sites and enzymatic reaction mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734185     DOI: 10.1089/aid.1995.11.115

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

2.  Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions.

Authors:  J L Gerton; S Ohgi; M Olsen; J DeRisi; P O Brown
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds.

Authors:  D Hazuda; P Felock; J Hastings; B Pramanik; A Wolfe; G Goodarzi; A Vora; K Brackmann; D Grandgenett
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase.

Authors:  D J Hazuda; P J Felock; J C Hastings; B Pramanik; A L Wolfe
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.

Authors:  R A Puras Lutzke; N A Eppens; P A Weber; R A Houghten; R H Plasterk
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  In Vivo Activity of Metal Complexes Containing 1,10-Phenanthroline and 3,6,9-Trioxaundecanedioate Ligands against Pseudomonas aeruginosa Infection in Galleria mellonella Larvae.

Authors:  Megan O'Shaughnessy; Magdalena Piatek; Pauraic McCarron; Malachy McCann; Michael Devereux; Kevin Kavanagh; Orla Howe
Journal:  Biomedicines       Date:  2022-01-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.